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Tumor lysis syndrome is a metabolic complication that may follow the initiation of cancer therapy. It commonly occurs
in hematological malignant patients particularly non-Hodgkin’s lymphoma and acute leukemia due to chemotherapy or
spontaneously. It is characterized by a biochemical abnormality such as hyperuricemia, hyperkalemia, hyperphosphatemia, and
hypocalcemia and its clinical outcome is directly related to these biochemical abnormalities. Prevention and treatment of tumor lysis
syndrome depend on immediate recognition of patients at risk. Therefore, identifying patients at risk and prophylactic measures
are important to minimize the clinical consequences of tumor lysis syndrome. Patients with low risk should receive hydration
and allopurinol. On the other hand patients with high risk should receive hydration and rasburicase in an inpatient setting. It is
important to start therapy immediately, to correct all parameters before cancer treatment, to assess risk level of patients for TLS,
and to select treatment options based on the risk level. In this review a comprehensive search of literatures was performed using
MEDLINE/PubMed, Hinari, the Cochrane library, and Google Scholar to summarize diagnostic criteria, incidence, predicting
factors, prevention, and treatment options for tumor lysis syndrome in patients with hematological malignancies.
1. Introduction
Tumor lysis syndrome (TLS) is a metabolic complication that
may follow the initiation of cancer therapy. It is character-
ized by a metabolic abnormality including hyperuricemia,
hyperkalemia, hyperphosphatemia, and hypocalcemia which
occurs due to rapid lysis of tumor cells and leads to severe
renal impairment, cardiac arrhythmia, or seizure and death
[1, 2]. It is one of the oncologic emergency encounters in
patients with hematological and other malignancies which
causes death [3]. Cytolysis of cancerous cells can be caused
by chemotherapy or it can occur spontaneously [4–6]. Spon-
taneous TLS is a rare occurrence but it may result in more
severe clinical outcomes because of the lack of benefit of
pretreatment [7].
Historically, TLS has been recognized in association with
leukemia therapy and first reported by Bedrna and Polca´k in
chronic leukemia patients treated with irradiation in 1929 [8].
TLS is most frequently associated with hematological malig-
nancies (HMs) such as lymphoma, leukemia, and multiple
myeloma (MM) [4, 9]. Besides this, TLS also occurs in high
proliferative and sensitive solid tumors [10].
This review summarizes the diagnostic criteria, patho-
physiology and clinical presentation, incidence, risk factors,
and prevention and treatment options of TLS in patients
with HMs. For this purpose, a comprehensive search of
literatures was performed using search terms like tumor lysis
syndrome, incidence, hematological malignancy, risk factor,
electrolyte abnormality, uric acid, allopurinol, rasburicase,
febuxostat, and combination of these terms by using MED-
LINE/PubMed, Hinari, the Cochrane library, and Google
Scholar. The relevant publications based on searches were
examined for this narrative review preparation. In addition
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to full articles, abstracts available related to TLS were also
included.
2. Definition and Classification of Tumor
Lysis Syndrome
Although there is a general consensus for a broad definition
of TLS as a set of metabolic complications that can occur in
rapidly proliferating neoplasm after anticancer therapy initi-
ation, there is no universal and standard diagnostic definition
and classification system for TLS. In 1993, Hande and Garrow
published the first formal definition [1]. However, it has some
limitations and was modified by Cairo and Bishop in 2004
[2] to formulate a uniformly used classification system for
TLS. Based on the Cairo and Bishop definition, TLS can be
classified as laboratory or clinical TLS. Laboratory defined
TLS is a type of TLS which is characterized by biochemical
changes without clinical manifestation. Patients can have
severe metabolic derangements without symptoms. These
require treatment. Clinical TLS is defined as biochemical
changes which are accompanied by clinical features and need
urgent management [2].
Cairo and Bishop defined laboratory TLS (LTLS) as an
abnormality of two or more of the following, occurring up to
three days before or seven days after chemotherapy: uric acid
(UA) ≥ 476mmol/L, potassium ≥ 6.0mmol/L, phosphorus
≥ 2.1mmol/L in children and ≥1.45mmol/L in adults, and
calcium ≤ 1.75mmol/L or 25% increase from baseline for
UA, potassium, and phosphorus and 25% decrease from
baseline for calcium. On the other hand, clinical TLS (CTLS)
is defined as a LTLS with one or more of the following abnor-
malities: creatinine more than 1.5 times upper limit normal
(ULN), cardiac arrhythmia/sudden death, and seizure [2].
The above definition of the Cairo and Bishop for TLS is
important to identify patients with laboratory evidence of
TLS but who do not require a specific therapeutic interven-
tion from those patients who experienced life-threatening
clinical abnormalities that required a specific intervention
(e.g., dialysis). However, the Cairo and Bishop classification
system has some shortcomings. Patients developing TLS
may not always have two or more abnormalities present at
once, but one metabolic derangement may precede another
abnormality. A 25% increase/decrease from baseline may not
always be significant if it does not result in a value outside
the normal range. Since hypocalcemiamay not be considered
as a direct consequence of TLS and is associated with high
phosphate levels, it is difficult to include as diagnostic criteria.
In 2011, Howard et al. modify the Cairo & Bishop
TLS classification by omitting the need for a 25% change
laboratory values from the baseline. According to Howard
and his colleagues, the 25% change from the baseline is not
clinically important, and they defined LTLS as presentation
of two or more metabolic abnormalities during the same 24-
hour period within 3 days before to 7 days after initiation of
therapy.On the other hand, LTLS plus an increased creatinine
level, seizures, cardiac dysrhythmia, or death constitutes
CTLS [11].
A uniform diagnosis criterion is important to determine
the exact incidence and risk classification of TLS. It becomes
more relevant for comparisons of new therapies for the
prevention and prophylaxis of TLS in the future. Even if there
is no uniformly accepted diagnostic and classification system
for TLS, the Cairo and Bishop diagnostic definition is often
used.The lack of universal definitions for diagnosis has made
the analysis of different studies examining TLS complicated
because of heterogeneity of diagnostic criteria, the variability
of patient study duration, variations in prophylactic treat-
ments, and broad variations in the type of therapy. It makes
comparisons between studies difficult [4, 12–15].
3. Pathophysiology and Clinical Presentation
of Tumor Lysis Syndrome
The main pathophysiology of TLS lies in the fact that malig-
nant cells are rich in purines, potassium, and phosphorus.
When these cells die spontaneously or secondary to therapy,
intracellular substances are released to extracellular fluid and
mediate the pathophysiology of TLS and its clinical compli-
cations. The increase in the concentration of potassium, UA,
and phosphate affects the normal homeostatic mechanisms
of the body and can result in numerous metabolic derange-
ments, impaired organ function, and associated morbidity.
The clinical presentation/outcome of TLS is directly linked to
the biochemical abnormalities which include hypocalcemia,
hyperkalemia, hyperphosphatemia, and hyperuricemia. Sev-
eral symptoms and abnormalities may appear due to TLS
including renal, cardiac, neurological, andmuscularmanifes-
tations. Although the signs and symptoms of TLS may occur
as early as a few hours after the start of chemotherapy, they are
more common 24 to 48 hours following initiation of treat-
ment [2, 16]. The pathophysiology and clinical presentation
of TLS depend on the combination of individual biochemical
abnormalities in the patient.
Cell lysis results in the release of enormous amounts
of potassium, which is concentrated intracellularly, into
extracellular fluid and results in hyperkalemia, which is one of
the key laboratorymanifestations of TLS. In addition, an early
peak in serum concentration may appear because of stress
due to radiotherapy or chemotherapy thatmay reduce adeno-
sine triphosphate levels and result in the release of potassium
before complete lysis of tumor cells [17, 18]. Hyperkalemia is
most severe component of TLS and may appear from 6 to 72
hours after chemotherapy initiation [17, 19]. Hyperkalemia
can affect the skeletal muscle and cardiac myocardium.
Patients with hyperkalemia present with fatigue, electro-
cardiogram abnormalities, and serious cardiac arrhythmias
including cardiac arrest. Severe hyperkalemia can adversely
affect skeletal and cardiac muscle function. ECG changes
include widening of the QRS complex and peaked T waves.
If severe hyperkalemia is not treated properly and timely,
it results in sudden death as a result of cardiac dys-
rhythmia [20, 21]. Hyperkalemia must be corrected rapidly
before potentially fatal ventricular arrhythmias occurred [22,
23].
Uric acid is a terminal product of the purine nucleotides
adenine and guanine in humans, which constitute the
backbone of nucleic acids. Purines are metabolized to
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hypoxanthine and xanthine via the action of enzymatic
activity of xanthine oxidase to UA [24, 25]. The rate of
UA clearance is highly dependent on the flow rate of the
glomerular filtrate through the renal tubule. Because of a high
cellular turnover in malignancy both spontaneously or due
to therapy, large amounts of purines are released and lead
to a rapid increase of UA (hyperuricemia). Hyperuricemia
develops from 48 to 72 hours after treatment initiation and
results in UA nephropathy form pathological urate crystal
deposition in the renal tubules resulting in acute kidney
injury (AKI) [16, 19, 26]. It is the main cause of renal failure
[27]. AKI is the most common manifestation of TLS [28].
Its incidence in patients with HMs varies from 30% to
69% depending on the relative proportions of patients with
leukemia, lymphoma, and MM [29–32].
The third metabolic abnormalities related to TLS is
hyperphosphatemia. Hyperphosphatemia may develop from
24 to 48 hours after treatment. The release of intracel-
lular phosphate overwhelms the normal renal threshold
for phosphate excretion and results in hyperphosphatemia.
Malignant hematologic cells may contain up to four times
more intracellular phosphate compared with normal mature
lymphoid cells [19]. Patients with spontaneous TLS may
have lower rates of hyperphosphatemia due to phosphate
uptake into rapidly dividing tumor cells compared to therapy-
related TLS [7, 25]. Acute destruction of tumor cells during
chemotherapy prevents the rapid reuse of phosphate for
newly synthesized tumor cells. When in excess, phosphorus
tends to bind to calcium and form calcium phosphate [2, 7].
The formation of calcium phosphate precipitates in the renal
tubules which leads to acute renal failure which is the most
significant complication resulting from hyperphosphatemia.
Hyperphosphatemiamay also result inmuscle cramps, tetany,
cardiac arrhythmia, and seizures [2, 16, 33, 34].
The other complication related to TLS is hypocalcemia. It
is frequently found in association with hyperphosphatemia
since phosphorus and calcium homeostasis are closely and
reciprocally linked [2, 16]. Hypocalcemia may present with
phosphate calcium crystal deposition and is rarely symp-
tomatic. However, it may present with symptoms as nausea,
vomiting, muscular hyperactivation such as spasms and
tetany, seizures, prolongation of QT interval on the ECG,
cardiac dysrhythmias, and alterations of mental status [34,
35].
In general, hyperkalemia is often the earliest laboratory
manifestation. Hyperkalemia and hyperphosphatemia result
directly from rapid malignant cell lysis. Hypocalcemia is a
consequence of acute hyperphosphatemia with subsequent
precipitation of calcium phosphate in soft tissues and UA is
the end product of purines metabolism in humans. Although
AKI remains the commonest, neurological or cardiac mani-
festations of TLS remain rare.
4. Incidence of Tumor Lysis Syndrome in
Hematological Malignancies
The incidence of TLS varies widely in HMs depending on
the underlying malignancy and the definition of TLS. It
ranges from case reports in certain chronic malignancies to
45% incidence reported in children with acute lymphoblastic
leukemia (ALL) which depends on patient’s risk factors and
diagnostic criteria [6, 14, 36]. TLS usually develops after
initiation of chemotherapy but there are also TLS occurring
spontaneously, that is, not requiring initiation of therapy.
Spontaneous TLS is typically observed in high-grade HMs
such as B-cell non-Hodgkin lymphoma (NHL) [7, 37, 38].
TLS occursmost frequently in high-gradeNHL and acute
leukemia and less commonly in chronic leukemia and MM.
This is supported by the following findings conducted in
different facilities in children and adult age groups. Wasim et
al. studied 50 patients diagnosed with HMs to determine the
frequency of TLS and reported the incidence of 14%, 4%, and
2% for acute leukemia, NHL, and chronic leukemia, respec-
tively [39]. In a multicenter cohort study of 153 high-risk
patients with acute leukemia, aggressive NHL, and Burkitt
leukemia/lymphoma, the overall incidence of TLS was found
to be 30.7% [32]. Sevinir et al. reviewed medical records of
327 children with NHL andALL retrospectively and reported
overall 5.8% incidence of TLS and an incidence of 15.9 % and
0.47% in NHL and ALL, respectively [40]. In another review
of 398 children diagnosed with ALL conducted by Al Bagshi
et al., the TLS incidence of 19% has been reported based on
Hande and Garrow definitions [12]. Bahoush et al. conducted
a study on 160 childrenwithALL to identify childrenwith low
risk for TLS and reported a 26% incidence of TLS [13]. Ahsan
Ejaz et al. also reported 32% incidence of TLS in acutemyeloid
leukemia (AML) patients using retrospective analysis of 183
patients [41].
A case report of TLS has been reported in chronic
leukemia and MM. Occasionally, in these malignancies,
highest incidence of TLS has been reported depending on the
chemotherapy undertaken. Blum et al. studied 116 patients
with chronic lymphocytic leukemia (CLL) treated with the
cyclin-dependent kinase inhibitor, flavopiridol, and reported
46% incidence of TLS [15]. In a retrospective study conducted
by Cairo et al. on 951 patients diagnosed with cancer highest
rate of TLS (42%) has been reported in MM among HMs [9].
5. Risk Factors and Predictors of Tumor
Lysis Syndrome
TLS occursmore frequently inHMs than in solid tumors.The
highest risk of developing TLS is observed in patients with
lymphoproliferative disorders with high proliferative rate and
high tumor sensitivity to chemotherapy, like B-cell ALL and
Burkitt’s lymphoma [42, 43]. Tumor burden, reflected by
serum lactate dehydrogenase (LDH) level, initial white blood
cell count (WBC), tumor size, and extensive bone marrow
involvement are the main predictor for development of TLS
in these patients [2]. When assessing the risk of TLS in a
particular patient, it is important to consider both the patient
and tumor related predictors of risk. The risk of developing
TLS is influenced by a number of characteristics including
tumor, patient, and therapy specific factors [11, 44]. Specific
risk factors are discussed below.
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5.1. Patient Related Factors. Patient related factors such as
dehydration status, advanced age, presence of splenomegaly,
presence of mediastinal mass, central nervous system (CNS)
and renal involvement, increased baseline creatinine level,
increased UA level, elevated LDH level, high WBC count,
and impaired kidney function can affect the development
of TLS [12, 14, 32, 45]. Older age is related to decreased
renal function and leads to a reduction in the glomerular
filtration rate.This decreased urine output leads to increasing
concentration of metabolites in blood [46]. A study con-
ducted to identify children with ALL at low risk for TLS
reported that CNS involvement, renal involvement, presence
of mediastinal mass, and baseline WBC count ≥ 20 × 109/L
were independent predicting factors with odds ratio of 11.6,
8.1, 4.3, and 3.1, respectively [13]. Another study conducted on
AML patients using multivariate analysis showed that WBC
count > 25 × 109/L, LDH level above ULN, UA > 7.5mg/dl,
and creatinine> 1.4mg/dl were identified as independent risk
factors for TLS development [28]. Truong et al. reviewed 398
patients aged ≤ 18 years diagnosed with ALL and reported
that splenomegaly, mediastinal mass, and initial WBC > 20×
10
9/L were found to be independent predictors of TLS [47].
In a pilot trial that investigated the safety of rituximab in
children with advanced mature B-NHL, patients with high
LDH had higher incidence of TLS and there was a strong
association between TLS development and high initial LDH,
with 13% of those with LDH < 2 × ULN versus 45% of those
with high LDH (≥2 × ULN) developing TLS [48].
5.2. Tumor Related Factors. Malignancies with high cancer
mass, bulky disease, large tumor burden, sensitivity of the
malignancy to chemotherapy, cancer stage, and rapid pro-
liferation rate of malignant cells are tumor specific factors
related to TLS [11, 41, 43, 44]. Increased tumor burden ismost
specific cancer risk factor which is demonstrated by large size,
elevated LDH, and increased WBC count. The quantity of
cellular contents released after the administration of effective
chemotherapy is increased when there is greater cancer mass
[43]. HMs with a high potential for cell lysis include high-
grade lymphomas and acute leukemias [32, 39]. Amulticenter
study of children and adolescents up to 18 years of age with
NHL indicated that patients with Burkitt’s lymphoma or B-
ALL had the highest incidence of TLS (8.4%) compared with
other NHL which was below 2%, suggesting that patients
with Burkitt’s lymphoma or B-ALL were at the highest risk
of developing TLS [42].
5.3. Therapy-Related Factors. Intensive polychemotherapy,
corticosteroids, intrathecal chemotherapy [5], radiotherapy,
and interferon [44] are cytotoxic therapies more frequently
associated with TLS. The use of certain cytotoxic agents such
as combination therapywith bortezomib, cyclophosphamide,
and dexamethasone in MM patients [49, 50] and ibrutinib,
fludarabine, and rituximab in CLL [15, 36] may result in TLS.
The introduction of more aggressive chemotherapy in the
management of HMs may contribute to an increase in inci-
dence of TLS. One study conducted to determine frequency
of TLS in aggressive and slow introduction chemother-
apy in children with ALL indicated that greater number
of patients developedTLS in aggressive compared to slow
induction chemotherapy (7/10 in aggressive and 3/10 in slow
chemotherapy) [51].
5.4. Risk Classification of TLS. Cairo et al. proposed TLS
risk classification system that combines multiple factors into
assessment of the patient’s risk of developing TLS. Based on
this risk classification system, a patient has no TLS at the time
of presentation categorized into three groups based on patient
related factors (preexisting renal) and disease related factors
(tumor type, tumor burden which is represented by tumor
stage, WBC counts, and LDH levels) (Table 1) [43].
Patients with lymphomas or leukemias considered to be
low risk disease were classified as being at an intermediate
risk of developing TLS if there was renal dysfunction and/or
renal involvement. Similarly, patients with leukemias and
lymphomas considered to be low risk disease were classified
as being at a high-risk of developing TLS if there was renal
dysfunction and/or renal involvement. Patients with low risk
disease and normal renal functionwould also be high-risk for
TLS if UA, phosphate, or potassium levels were elevated [43].
Patients at low and intermediate risk can be treated with
hydration and allopurinol while high-risk patients are treated
with rasburicase and increased hydration [43, 52].
6. Prevention and Treatment
TLS prophylaxis is recommended to all patients with HMs
undergoing chemotherapy. Recognizing risk factors is an
important step to prevent TLS. It is important to minimize
or eliminate factors that may result in a greater risk of
TLS. Prevention is the best treatment for TLS. Treatment
and prevention of TLS consist of using medications that
decreaseUA (hypouricemic agents), electrolytemanagement,
and adequate hydration before and following chemotherapy
[11, 44, 53]. Patients with low risk should receive hydration
and allopurinol. Patients at high risk should receive hydration
and rasburicase in an inpatient setting. In order to avoid
xanthine accumulation and lack of substrate for rasburicase,
concomitant allopurinol should not be administered [44].
6.1. Hydration. Adequate hydration is the first measure
undertaken to increase intravascular volume and prevent-
ing TLS. This decreases extracellular concentrations of UA,
phosphorus, and potassium and enhances renal blood flow
tomaintain sufficient glomerular filtration rate and urine out-
put. When possible, intravenous hydration should be started
at least 24 to 48 hours prior to chemotherapy initiation and
continued during chemotherapy, depending on tumor type
or the patient’s clinical condition. In patients with underlying
acute kidney injury or cardiac dysfunction, IV hydration can
lead to potentially dangerous fluid overload. In this occasion,
close monitoring and follow-up are mandatory. If adequate
urine output cannot be achieved with IV hydration alone,
diuretics may be important to achieve the desired outcome
[2, 16, 54]. Since these diuretics may contribute uric acid or
calcium phosphate precipitation in renal tubules, the patient
must be well hydrated.
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Table 1: Patients risk classification in HMs.
Risk group Type of HMs
High risk
(i) Advanced stage Burkitt’s lymphoma/leukemia (B-ALL)
(ii) Lymphoblastic lymphoma with LDH ≥ 2 × ULN
(iii) Early stage Burkitt’s lymphoma/leukemia with LDH ≥ 2 × ULN
(iv) ALL with WBC count ≥ 100 × 109/L or less if the baseline elevation of LDH is twice ULN
(v) AML with WBC count ≥ 100 × 109/L
(vi) Diffuse large B-cell lymphoma (DLBCL) with an elevated baseline LDH of twice ULN, and
bulky disease
Intermediate risk
(i) AML with a WBC between 25 × 109/l and 100 × 109/l or <25 × 109/L if the baseline elevation of
LDH is twice ULN
(ii) ALL with WBC < 100 × 109/L and an LDH of less than twice ULN
(iii) Early stage Burkitt lymphoma/leukemia with an LDH of less than twice ULN
(iv) DLBCL with a baseline increase in LDH of twice ULN but nonbulky disease
(v) CLL with WBC ≥ 50 × 109/L
Low risk
(i) Indolent lymphomas
(ii) CLL
(iii) Chronic myelogenous leukemia (CML)
(iv) AML with WBC count < 25 × 109/L and an LDH elevated to less than twice ULN
(v) MM
Source. Customized from recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant
diseases: an expert TLS panel consensus. BJH, Cairo MS et al. 149, 578–586, copyright 2010 Blackwell Publishing Ltd.
6.2. Hypouricemic Agents
6.2.1. Allopurinol. Allopurinol is begun 2-3 days prior to
chemotherapy and continued for 10–14 days as a first-line
treatment of hyperuricemia. It is a competitive inhibitor of
xanthine oxidase, which is an enzyme used to break down
hypoxanthine to xanthine and xanthine to UA. Although
allopurinol is effective at inhibiting new UA formation, it
is not effective in reducing existing UA level. However,
inhibition of xanthine oxidase may result in a buildup of
xanthine and hypoxanthine concentration, which is less
soluble than UA, and form crystals that deposit in the
kidney leading to xanthine nephropathy [55, 56].The effect of
allopurinol is relatively slow, taking several days to produce a
reduction inUA level compared to rasburicase. Amulticenter
study conducted on adults at risk for TLS demonstrated
that allopurinol had significantly lower response rate for UA
than rasburicase (66% versus 87%). The mean UA reduction
within four hours was also lower in allopurinol (14%) than
rasburicase (88%) [57].
6.2.2. Rasburicase. Rasburicase is begun when allopurinol is
ineffective for hyperuricemia treatment. It is a pure recom-
binant form of urate oxidase, an enzyme responsible for
the breakdown of UA into allantoin, which is easily soluble
and readily removed [58]. Rasburicase is safe and effective
in decreasing serum UA levels in lymphoma and leukemia
patients undertaking chemotherapy [48, 57–61]. Rasburicase
can be used as hypouricemic therapy with hydration in high-
risk patient and patients with laboratory and clinical TLS
[43, 44]. The primary advantage of urate oxidase is its rapid
start of the action. It rapidly lowers UA levels, usually within
four hours of administration. It provides better control of
UA compared to allopurinol. A randomized study conducted
to compare rasburicase and allopurinol in children with
lymphoma and leukemia indicated that patients randomized
to rasburicase had better reduction of initial plasmaUA levels
compared to allopurinol in four hours after the first dose
(86% versus 12% reduction). In this study the rasburicase
group (AUC
0–96 of 128±70mg/dL hour) experienced 2.6-fold
less exposure to UA compared to allopurinol group (329 ±
129mg/dL hour) [58]. Another multicenter study conducted
to evaluate safety and efficacy of rasburicase showed that 99%
of hyperuricemic patients responded to rasburicase treat-
ment. Similarly all patients (nonhyperuricemic)who received
rasburicase prophylactically maintained low uric acid levels
despite ongoing chemotherapy [62]. One of the disadvantages
of rasburicase is its high cost [63]. Secondly, it should not
be used in patients with glucose-6-phosphate dehydrogenase
(G6PD) deficiency due to the risk of hemolysis following its
administration. Rasburicase breaks down UA and results in
the production of hydrogen peroxide. In patients with G6PD
deficiency, it may result in an increased risk of hemolytic
anemia and methemoglobinemia [64–66].
6.2.3. Febuxostat. Febuxostat is a novel new nonpurine selec-
tive inhibitor of xanthine oxidase, which is a promising
alternative to allopurinol in patients who are unable to
tolerate allopurinol, have inadequate response to allopuri-
nol, or have renal dysfunction. It decreases and maintains
serum UA levels more effectively than allopurinol in patients
with hyperuricemia. It is more effective than allopurinol in
patients with impaired renal function. Febuxostat was safe
and effective in preventing or reversing hyperuricemia in
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patients with HMs who were undergoing chemotherapy and
at an intermediate risk to develop TLS [67–69]. Schumacher
et al. conducted randomized and double blinded trial to
study the effect of febuxostat and allopurinol in subjects
with hyperuricemia and gout and reported that significantly
higher percentages of subjects treated with febuxostat 240mg
(69%) attained serum urate levels < 6.0mg/dl compared with
allopurinol (22%). About 60% of subjects with impaired renal
function treated with febuxostat 240mg achieved < 6.0mg/dl
compared with those treated with 100mg of allopurinol (0%)
[70].
6.3. Urine Alkalinization. Alkalinization is commonly used
as part of the preventativemeasure of TLS, since this increases
the urine pH which makes UA more soluble and less likely
to precipitate in the renal tubules. However, alkalinizing
the urine may facilitate calcium phosphate deposition in
malignant patients with severe hyperphosphatemia [71].
Urinary alkalization can cause a xanthine nephropathy by
decreasing the solubility of xanthine, a precursor of UA.
Alkalinization of the urine assists in decreasing the incidence
of UA nephropathy and subsequent renal failure by reducing
UA crystallization. In alkaline environments, UA remains
ionized. Thus, it is more water soluble and more readily
excreted by the kidneys [2, 16]. However, alkalinization of
the urine, once a common treatment for TLS, is no longer
routinely recommended because it may be associated with
metabolic acidosis and calcium phosphate precipitation [25,
72].
6.4. Electrolyte Management. Another measure is the dis-
continuation of agents that may worsen the patient’s con-
dition with experience of TLS. Electrolyte supplementation,
particularly potassium and phosphorus products, should be
stopped and removed from IV fluids to avoid the risk of
worsening electrolyte abnormalities. Hyperphosphatemia is
managed with phosphate binders such as aluminum hydrox-
ide which will decrease the gut absorption of phosphate.
Usually, treatments of hyperphosphatemia will self-correct
any related hypocalcemia. Calcium itself should not be
administered as it may precipitate metastatic calcifications
[23, 73, 74].
Mild hyperkalemia can be managed with sodium
polystyrene sulfonate. Treatments for severe hyperkalemia
with or without ECG changes include hypertonic glucose and
insulin, loop diuretics, and bicarbonate. Hypertonic glucose
and insulin will shift potassium from the extracellular to
the intracellular space. Sodium bicarbonate shifts potassium
intracellularly and a slight alkalinization favors distal
tubule secretion as well. Loop diuretics promote potassium
excretion [22, 73].
6.5. Dialysis. A patient who does not respond to the
above measures may need renal replacement therapy, such
as hemodialysis, to manage electrolyte abnormalities and
hyperuricemia and treat renal failure associated with TLS.
Hemodialysis should be considered for every patient with
excessively elevated UA, phosphate, and/or potassium not
responsive to pharmacologic intervention and in those
patients in whom acute renal failure develops despite preven-
tion to control volume overload, electrolyte abnormalities,
and uremia [72]. Dialysis may be initiated prophylacti-
cally before the development of overt uremic symptoms in
response to severe, progressive hyperphosphatemia or severe
symptomatic hypocalcemia. Frequent dialysis is recom-
mended considering the continuous release into the blood-
stream of purine products, potassium, and other metabolites
and electrolytes resulting from lysed tumor cells. The timing
of dialysis and the dialysis dose should be linked to the purine
generation rate [44, 75].
7. Conclusion and Recommendation
Tumor lysis syndrome is a common and life-threatening
event in patients with lymphoma and leukemia undertak-
ing chemotherapy. The incidence is increasing because of
more effective cancer treatments and needs due attention in
these malignancies. There must be standard and universally
accepted diagnostic criteria for TLS to start therapy imme-
diately, to correct all parameters before cancer treatment, to
assess risk level of patients for TLS, and to select treatment
options based on the risk level. If the patient is at low
and intermediate risk, IV fluid with allopurinol is given
with close monitoring while high-risk patients are treated
with rasburicase and increased hydration. Dialysis is the last
option if the other treatment options failed. Since TLS is
potentially fatal, close monitoring of patients at risk before,
during, and after their course of chemotherapy is critical.
Identifying patients at risk and prophylactic measures are
important to minimize the clinical consequences of this
syndrome.
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